{
    "clinical_study": {
        "@rank": "89186", 
        "arm_group": {
            "arm_group_label": "TGR-1202 + Obinutuzumab + Chlorambucil", 
            "arm_group_type": "Experimental", 
            "description": "TGR-1202 is an oral daily dose with obinutuzumab at a fixed IV infusion and chlorambucil as an oral dose on specified days."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in\n      combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic\n      leukemia."
        }, 
        "brief_title": "Efficacy and Safety of TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed Chronic Lymphocytic Leukemia (CLL)\n\n          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2\n\n          -  Ability to swallow oral medication\n\n        Exclusion Criteria:\n\n          -  Known hepatitis B virus, hepatitis C virus or HIV infection\n\n          -  Primary central nervous system lymphoma or known intracranial involvement\n\n          -  Autologous hematologic stem cell transplant within 3 months of study entry or\n             Allogeneic hematologic stem cell transplant within 12 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100852", 
            "org_study_id": "TGR-GA-106"
        }, 
        "intervention": {
            "arm_group_label": "TGR-1202 + Obinutuzumab + Chlorambucil", 
            "description": "TGR-1202:  Oral dose Obinutuzumab:  IV infusion Chlorambucil:  Oral dose", 
            "intervention_name": "TGR-1202 + Obinutuzumab + Chlorambucil", 
            "intervention_type": "Drug", 
            "other_name": [
                "Obinutuzumab:  Gazyva", 
                "Chlorambucil:  Leukeran"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Chlorambucil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntsville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35805"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)", 
        "overall_contact": {
            "email": "clinicalsupport@tgtxinc.com", 
            "last_name": "TG Therapeutics Clinical Support Team", 
            "phone": "212-554-4484"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities", 
            "measure": "Maximum Tolerated Dose acceptable for participants", 
            "safety_issue": "No", 
            "time_frame": "28 days (1 cycle of therapy)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100852"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the overall response rate (ORR) in patients with chronic lymphocytic leukemia treated with TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil", 
            "measure": "Overall Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "source": "TG Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TG Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}